Plaquetec

Plaquetec pioneers a method to profile the underlying biology of coronary artery disease, building cohorts to endotype the disease for the first time. Coronary artery disease is a leading cause of global morbidity and mortality, accounting for 600,000 deaths in the United States every year. Plaquetec's unique approach enables the identification of new disease-specific drug targets, paving the way for a new era of precision medicine for millions of patients with CAD. By profiling the biology of coronary artery plaques, the company creates detailed biological characterizations that distinguish between different disease subtypes, or endotypes, which can inform targeted therapeutic development. This methodology represents a shift from treating coronary artery disease as a single condition toward understanding its heterogeneous biological mechanisms, enabling researchers and pharmaceutical partners to identify specific molecular targets relevant to particular patient populations. The company's approach to endotyping has implications for drug discovery, biomarker development, and stratified medicine, potentially improving outcomes for patients who do not respond adequately to existing standard-of-care treatments. Founded in 2008 and headquartered in Cambridge, United Kingdom, Plaquetec has raised $13.0M in Series A funding from investors including Future Fund, Ipex Capital, and Paj Lewis. The team comprises 4 employees.